

**AUSTRALIAN PATHOLOGY UNITS  
AND TERMINOLOGY**

(APUTS)

**Reporting Terminology and Codes  
Genetic Pathology**

(v2.1)



ISBN: Pending

State Health Publication Number (SHPN): Pending

Online copyright

© RCPA 2014

This work (Standards and Guidelines) is copyright. You may download, display, print and reproduce the Standards and Guidelines for your personal, non-commercial use or use within your organisation subject to the following terms and conditions:

1. The Standards and Guidelines may not be copied, reproduced, communicated or displayed, in whole or in part, for profit or commercial gain.
2. Any copy, reproduction or communication must include this RCPA copyright notice in full.
3. No changes may be made to the wording of the Standards and Guidelines including commentary, tables or diagrams. Excerpts from the Standards and Guidelines may be used. References and acknowledgments must be maintained in any reproduction or copy in full or part of the Standards and Guidelines.

Apart from any use as permitted under the Copyright Act 1968 or as set out above, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to RCPA, 207 Albion St, Surry Hills, NSW 2010, Australia.

This material contains content from LOINC® (<http://loinc.org>). The LOINC table, LOINC codes and LOINC panels and forms file are copyright © 1995-2012, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and available at no cost under the license at <http://loinc.org/terms-of-use>.

This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO®). All rights reserved. SNOMED CT was originally created by The College of American Pathologists. IHTSDO®, SNOMED® and SNOMED CT® are registered trademarks of the IHTSDO

First published: February, 2013, 1st Edition (version 1.0)

# Terminology for Reporting Pathology: Generic Genetic Pathology Report

TRIM Document #: D156347

## Document History:

Version	Reason for Change	Author	Date
1.0	Initial Terminology for Microbiology: Organisms mapped to SNOMED CT, published by the RCPA Pathology Units and Terminology Standardisation Project.	Michael Legg / Dr Christiana Swanepoel	12-Feb-13
2.0	Added Document Revision History worksheet. Changed file name from PUTS-Genetics-Report-information-model to APUTS Genetics Report terminology reference set.	Donna Moore	06-Jun-14
2.1	After public feedback and approval by PITUS steering committee the following changes were made:  - added comment for missing LOINC codes marked as 'XXXXX-X'. Comment added was 'LOINC code pending. Currently no code is available.'	Donna Moore	28-Oct-14



Generic Genetic Pathology Report Format											
Example answers / response / Comments		LOINC	Component	Property	Timing	System	Scale	Method	Class	LongName	
<b>Specimen</b>		31208-2	Specimen source	Prid	Pt	XXX	Nom		SPEC	Specimen source [Identifier] of Unspecified specimen	
Specimen Type must be stated. This could be any of blood, cells, fluids [state type], and could include tissue, frozen sample, formalin fixed paraffin Embedded sample. etc Note the complication that a sample from a fetus may contain DNA from both the fetus AND the mother											
<b>Request</b>											
<b>Genetic disease /condition assessed</b>		51967-8	Genetic disease assessed	ID	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	Genetic disease assessed [Identifier] in Blood or Tissue by Molecular genetics method	
A coded disease (recommend SNOMED) which is known to be caused by or identified by genomic DNA Markers. ex.: SCTID: 190905008   Cystic fibrosis   alternative coding: HGNC:1881   cystic fibrosis modifier 1											
<b>Clinical question</b>		53577-3	Reason for study additional note	Txt	Pt	Bld/Tiss	Nar	Molgen	HL7.GENETICS	Reason for study additional note [Text] in Blood or Tissue by Molecular genetics method Narrative	
The freeform text that entered by orderer to further annotate the coded Reason for Study associated with an ordered test. Note: Although "Clinical Question" is shown as freeform text in this version, it is anticipated that a future "structured request framework" will be developed											
<b>Test</b>											
<b>Genetic Test</b>											
<b>Genomic Source class</b>		48004-6	DNA sequence variation	Find	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	DNA sequence variation in Blood or Tissue by Molecular genetics method	
The genomic class of the specimen being analyzed:											
<b>Genetic Level</b>		XXXXX-X									
Whole Genome											
Chromosome											
Intergenic											
Gene											
<b>Gene Name or Locus</b>											
<b>Coding System</b>		XXXXX-X									
HGNC Gene ID		48018-6	Gene identifier	ID	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	Gene [Identifier] in Blood or Tissue by Molecular genetics method	
e.g. BRCA1 => HGNC:1100											
NCBI DNA Sequence Variation Number (dbSNP ids - rs#)		48003-8	DNA sequence variation identifier	ID	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	DNA sequence variation identifier [Identifier] in Blood or Tissue by Molecular genetics method	
A DNA Marker Identifier conveys a universal or standard repository identifier for definitive characteristics of a DNA Marker. (recommend using NCBI dbSNP ids - rs#)											
NCBI Genomic reference sequence		48013-7	Genomic reference sequence identifier	ID	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	Genomic reference sequence [Identifier] in Blood or Tissue by Molecular genetics method	
This field carries the ID for the genomic reference sequence. The genomic reference sequence is a contiguous stretch of chromosome DNA that spans all of the exons of the gene and includes transcribed and non transcribed stretches. For this ID use either the NCBI genomic nucleotide RefSeq IDs with their version number (see: NCBI.NLM.NIH.Gov/RefSeq) or use the LRG identifiers, without transcript (i or p) extensions - when they become available. (See- Report sponsored by GENZPHEN at the European Bioinformatics Institute at Hinxton UK April 24-25, 2008). The NCI RefSeq genomic IDs are distinguished by a prefix of "NG" for genes from the nuclear chromosomes and prefix of "NC" for genes from mitochondria. The LRG Identifiers have a prefix of "LRG_". Mitochondrial genes are not in the scope of LRG											
DMD (ref. sequence NM_000109)											
CFTR (ref. sequence NM_000492)											
HTT (ref. sequence NM_002111)											
<b>Code (actual code for the genetic test)</b>		XXXXX-X									
HGNC:1100 for BRCA1											
NM_000109 for DMD (ref. sequence)											
<b>Additional information</b>		XXXXX-X									
<b>Genetic Test Method</b>		XXXXX-X									
<b>Category</b>		XXXXX-X									
<b>Mutational analysis</b>		XXXXX-X									
The intention is to expand each of the following by one sublevel analogous to Chromosomal conditions so as to hold more detailed information relevant to each Type of Mutational Analysis (Next level of detail for these Mutational Analysis tests has not yet been shown)											
Tests for multiple mutations ...		XXXXX-X									
Test for selected mutations only ...		XXXXX-X									
Assay for size of triplet repeat only ...		XXXXX-X									
<b>Chromosome microarray (CMA)</b>											
Microarray platform		62375-1	Microarray platform	ID	Pt	Bld/Tiss	Nar	Molgen	HL7.CYTOGEN	Microarray platform [Identifier] in Blood or Tissue by Molecular genetics method Narrative	
Microarray platform version number		62376-9	Microarray platform version number	ID	Pt	Bld/Tiss	Nar	Molgen	HL7.CYTOGEN	Microarray platform version number in Blood or Tissue by Molecular genetics method Narrative	
Base pair start coordinate		62381-9	Base pair start coordinate	Num	Pt	Bld/Tiss	Qn	Molgen	HL7.CYTOGEN	Base pair start coordinate [#] in Blood or Tissue by Molecular genetics method	
Base pair end coordinate		62381-9	Base pair end coordinate	Num	Pt	Bld/Tiss	Qn	Molgen	HL7.CYTOGEN	Base pair end coordinate [#] in Blood or Tissue by Molecular genetics method	
Flanking normal region before start		62382-7	Flanking normal region before start	Find	Pt	Bld/Tiss	Nom	Molgen	HL7.CYTOGEN	Flanking normal region before start in Blood or Tissue by Molecular genetics method	
<b>Analysis by Chromosomal Banding</b>											
ISCN band level [#]		62358-7	ISCN band level	Num	Pt	Bld/Tiss	Ord	Molgen	HL7.CYTOGEN	ISCN band level [#] in Blood or Tissue Qualitative by Molecular genetics method	
Chromosome band involved start		62379-3	Chromosome band involved start	Find	Pt	Bld/Tiss	Nom	Molgen	HL7.CYTOGEN	Chromosome band involved start in Blood or Tissue by Molecular genetics method	
Chromosome band involved end		62380-1	Chromosome band involved end	Find	Pt	Bld/Tiss	Nom	Molgen	HL7.CYTOGEN	Chromosome band involved end in Blood or Tissue by Molecular genetics method	
Chromosome banding method		62359-5	Chromosome banding method	Type	Pt	Bld/Tiss	Nom	Molgen	HL7.CYTOGEN	Chromosome banding method [Type] in Blood or Tissue by Molecular genetics method	
Cells analyzed [#]		62360-3	Cells analyzed	Num	Pt	Bld/Tiss	Qn	Molgen	HL7.CYTOGEN	Cells analyzed [#] in Blood or Tissue by Molecular genetics method	
Cells counted [#]		62361-1	Cells counted	Num	Pt	Bld/Tiss	Qn	Molgen	HL7.CYTOGEN	Cells counted [#] in Blood or Tissue by Molecular genetics method	
Cells karyotyped.total [#]		55199-4	Cells karyotyped.total	Num	Pt	Bld/Tiss	Qn	MOLPATH	HL7.CYTOGEN	Cells karyotyped.total [#] in Blood or Tissue	
Colonies counted [#]		62362-9	Colonies counted	Num	Pt	Bld/Tiss	Qn	Molgen	HL7.CYTOGEN	Colonies counted [#] in Blood or Tissue by Molecular genetics method	
Mosaicism detected		62363-7	Mosaicism detected	Find	Pt	Bld/Tiss	Nom	Molgen	HL7.CYTOGEN	Mosaicism detected in Blood or Tissue by Molecular genetics method	
<b>Analysis by in situ hybridisation</b>											

Generic Genetic Pathology Report Format											
	Cell phase	62368-6	Cell phase	Type	Pt	Bld/Tiss	Nom	Molgen	HL7.CYTOGEN	Cell phase [Type] in Blood or Tissue by Molecular genetics method	
	Probe gene name	62370-2	FISH probe gene name	ID	Pt	Bld/Tiss	Nom	Molgen	HL7.CYTOGEN	FISH probe gene name [Identifier] in Blood or Tissue by Molecular genetics method	
	Probe locus	62371-0	FISH probe locus	ID	Pt	Bld/Tiss	Nom	Molgen	HL7.CYTOGEN	FISH probe locus [Identifier] in Blood or Tissue by Molecular genetics method	
	Probe vendor	62372-8	FISH probe vendor	ID	Pt	Bld/Tiss	Nom	Molgen	HL7.CYTOGEN	FISH probe vendor [Identifier] in Blood or Tissue by Molecular genetics method	
	Cells analysed	62360-3	Cells analyzed	Num	Pt	Bld/Tiss	Qn	Molgen	HL7.CYTOGEN	Cells analyzed [#] in Blood or Tissue by Molecular genetics method	
	Other										
			<i>Details of test method not already specified (e.g. MLPA or direct DNA sequencing or list mutations searched for)</i>								
	Linkage studies	XXXXX-X									
	Genetic Test Result										
	Cytogenetics										
	Karyotype analysis result in ISCN expression	62356-1	Chromosome analysis result in ISCN expression	Find	Pt	Bld/Tiss	Nom	Molgen	HL7.CYTOGEN	Chromosome analysis result in ISCN expression in Blood or Tissue by Molecular genetics method	
		47,XY,+2									
		46,XY,-18,+der(13q18q),t(13;18)(13q18q;13p18p)pat									
	Microarray analysis result in ISCN expression	XXXXX-X									
		arr 16p13.11(14,817,706-16,649,713)x3 dn									
		arr 1p36.22p31.3(9,240,258-67,037,576)x2 hnz									
	Molecular Genetics										
	DNA sequence variation type	48019-4	DNA sequence variation type	Type	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	DNA sequence variation type in Blood or Tissue by Molecular genetics method	
			<i>Codified type for associated DNA Marker. DNA Marker's use the HGVS notation which implies the DNA Marker Type, but the concurrent use of this code will allow a standard and explicit type for technical and display convenience. 1 Wild type - LA9658-1 2 Deletion - LA6692-3 3 Duplication - LA6686-5 4 Insertion - LA6687-3 5 Insertion/Deletion - LA6688-1 6 Inversion - LA6689-9 7 Substitution - LA6690-7</i>								
	HGVS DNA Sequence Variation	48004-6	DNA sequence variation	Find	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	DNA sequence variation in Blood or Tissue by Molecular genetics method	
			<i>Human Genome Variation Society (HGVS) nomenclature for a single DNA marker. The use of the nomenclature must be extended to describe non-variantions (aka. wild types) see samples for wild type examples. *Massively Parallel Sequencing (MPS) is anticipated to go here, but we have postponed specific inclusion pending the outcome of the MPS Working Party recommendations</i>								
			<i>e.g. c.3869A&gt;C heterozygote</i>								
	DNA region name	47999-8	DNA region name	ID	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	DNA region name [Identifier] in Blood or Tissue by Molecular genetics method	
			<i>A human readable name for the region of interest. Typically Exon #, Intron # or other. NOTE: This is not standardized and is mainly for convenience and display purposes.</i>								
	RNA										
			<i>This section is anticipated to hold the results of RNA-specific changes, such as RNA Editing, Transcriptionomic results, etc</i>								
	Amino acid change	48005-3	Amino acid change	Find	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	Amino acid change in Blood or Tissue by Molecular genetics method	
			<i>Human Genome Variation Society (HGVS) nomenclature for an amino acid sequence. This value is derivable from the DNA Marker value if available. It is provided for convenience. The use of the nomenclature must be extended to describe non-variantions (aka. wild types) see samples for wild type examples.</i>								
	Genomic RefSeq String	48013-7	Genomic reference sequence identifier	ID	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	Genomic reference sequence [Identifier] in Blood or Tissue by Molecular genetics method	
			<i>Definition: Carries the literal string that represents the DNA sequence that is the basis for deciding what is a different (a variation) in the study subject The same information can also be reported more compactly by reference (see LOINC code 48013-7) if the reference sequence has been catalogued by a registration authority such as RefSeq at NCBI a. Reference sequences can be quite long Example answer: 241 GGAGTAATCA GCAACTCAGG GGGACCTGTA CGAGTCTATA GCCTACCTGG TCGAGAAAAC 301 TATTCTCAG TAGATGCCAA TGGCATCCAG TCTCAAATGC TTTCTAGATG GTCTGCTTCT 361 TTCACAGTAA CTA</i>								
	Amino acid change type	48006-1	Amino acid change type	Type	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	Amino acid change type in Blood or Tissue by Molecular genetics method	
	Allelic State	53034-5	Allelic state	Find	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	Allelic state in Blood or Tissue by Molecular genetics method	
			<i>*Includes Copy Number Variation [CNV], Loss of Heterozygosity [LOH], Quantitative gene dosage*</i>								
	Result modifier	62364-5	Test performance information	Find	Pt	XXX	Nar		HL7.CYTOGEN	Test performance information in Unspecified specimen Narrative	
	RNA/Protein consequences										
	Reports										
	Co-occurrence with deleterious mutations										
	Species conservation										
	Biochemical										
			<i>This modifier can be used to correlate genetic findings with (e.g.) pharmacogenomic or biochemical results</i>								
	Biophysical change										
	In-silico analyses										
	RNA Studies										
	Functional studies										
	Control data										
	Segregation data										
	Loss of normal allele in cancer										
	Genetic Test Interpretation										
	Limitations and Disclaimers (compulsory)	XXXXX-X									
			<i>This section would describe the status of the result. Has it been validated? Is it research-use only? Are there known weaknesses? Is this study partial, in progress, complete, etc</i>								
	Result interpretation (compulsory)										
			<i>This section summarises the laboratory findings. What were the results of testing? What are the biological and genetic implications of this result?</i>								

**Generic Genetic Pathology Report Format**

	Genetic Screen findings (optional)	19102-3	Genetic screen	Find	Pt	XXX	Nar	Molgen	MOLPATH	Genetic screen in Unspecified specimen by Molecular genetics method Narrative
	Carrier status summary (optional)	53039-4	Genetic disease analysis overall carrier interpretation	Imp	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	Genetic disease analysis overall carrier interpretation [interpretation] in Blood or Tissue by Molecular genetics method
	<i>Carrier Identification interpretation of all identified DNA Markers and/or Individual Alleles along with any known clinical information for the benefit of advising clinicians in understanding the results overall.</i>									
	Sequence variation summary (optional)	53037-8	Genetic disease sequence variation interpretation	Imp	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	Genetic disease sequence variation interpretation [interpretation] in Blood or Tissue by Molecular genetics method
	Clinical Interpretation (compulsory)	51968-6	Genetic disease analysis overall interpretation	Imp	Pt	Bld/Tiss	Nom	Molgen	HL7.GENETICS	Genetic disease analysis overall interpretation [interpretation] in Blood or Tissue by Molecular genetics method
	<i>This section summarises the clinical significance (if any) of the laboratory findings. It can take into account Family History or Clinical History.</i>									
	Genotype clinical interpretation (optional)									
	Phenotype clinical interpretation (optional)									
	Conclusion (optional)	62365-2	Diagnostic impression	Imp	Pt	XXX	Nar	Molgen	HL7.CYTOGEN	Diagnostic impression [interpretation] in Unspecified specimen by Molecular genetics method Narrative
	<i>This is the final "tie it all together" field, if not already done so above.</i>									
	Interpretation modifier	XXXXX-X								
	<i>As for Result modifier, see above</i>									

# Genetic Pathology Report Format

## Specimen (compulsory)

Specimen Type must be stated. This could be any of blood, cells, fluids (state type), and could include tissue, frozen sample, formalin fixed paraffin Embedded sample, etc.  
Note the complication that a sample from a fetus may contain DNA from both the fetus AND the mother

## Request

Genetic disease/condition assessed

\*A coded disease (recommnd SNOMED) which is known to be caused by or identified by genomic DNA Markers, eg SCT 19095608 | Cystic fibrosis |

Clinical question

Freeform text entered by requester to further annotate the coded Reason for Study associated with an ordered test.

Note: Although "Clinical Question" is shown as freeform text in this version, it is anticipated that a future "structured request framework" will be developed

## Test

Genetic Test

Genetic Source class

Whole Genome

Chromosome

Intergenic

Gene

Gene Name or Locus

Coding System

Code (actual code for the genetic test)

Additional Information

Genetic Test Method

Category

Mutational analysis

The intention is to expand each of the following by one sublevel analogous to Chromosomal conditions so as to hold more detailed information relevant to each Type of Mutational Analysis. (Best level of detail for these Mutational Analysis tests has not yet been shown)

Tests for multiple mutations

Test for selected mutations only

Assay for size of triplet repeat only

Chromosomal microarray (CMA)

Microarray platform

Microarray platform version number

Base pair start coordinate

Base pair end coordinate

Flanking normal region before start

Analysis by Chromosome Banding

ISCN band level [ # ]

Chromosome band involved start

Chromosome band involved end

Chromosome banding method

Cells analysed [ # ]

Cells counted [ # ]

Cells karyotyped total [ # ]

Colonies counted [ # ]

Mosaicism detected

Analysis by in situ hybridisation

Cell phase

Probe gene name

Probe locus

Probe vendor

Cells analysed

Functional analysis

DNA methylation

DNA transcription

Linkage studies

Other (Details of test method not already specified (e.g. MLPA or direct DNA sequencing or list mutations searched for))

Genetic Test Result

Cytogenetics

Karyotype analysis result in ISCN expression

47,XY,-2

Microarray analysis result in ISCN expression

arr 16p13.11(14,817,706-16,649,713)x3 dn

Microarray analysis result in ISCN expression

arr 1p36.22p31.3(9,240,268-67,037,576)x2 hmx

Molecular Genetics

DNA sequence variation type

\*Coded type for associated DNA Marker. DNA Marker's use the HGVS notation which implies the DNA Marker Type, but the concurrent use of this code will allow a standard and explicit type for technical and display convenience.

1 Wild type - LA668-1 2 Deletion - LA669-3 3 Duplication - LA668-5 4 Insertion - LA667-3 5 Inversion/Deletion - LA668B-1 6 Inversion - LA668B-9 7 Substitution - LA669-7

HGVS DNA Sequence Variation

Human Genome Variation Society (HGVS) nomenclature for a single DNA marker. The use of the nomenclature must be extended to describe non-variations (aka. wild types) see samples for wild type examples. e.g. c.3869A<C> heterozygote

\*Massively Parallel Sequencing [NGS/WGS] is anticipated to go here, but we have postponed specific inclusion pending the outcome of the MPS Working Party recommendations.

DNA region name

\*A human readable name for the region of interest. Typically Exon #, Intron # or other. NOTE: This is not standard and is, mainly, for convenience and display purposes.

RNA

Amino acid change

This section is anticipated to hold the results of RNA-specific changes, such as RNA Editing, Transcriptional results, etc.

\*Human Genome Variation Society (HGVS) nomenclature for an amino acid sequence. This value is derivable from the DNA Marker value if available. It is provided for convenience. The use of the nomenclature must be extended to describe non-variations (aka. wild types) see samples for wild type examples.

Genomic RefSeq String

\*Definition: Carries the literal string that represents the DNA sequence that is the basis for deciding what is a different (a variation) in the study subject. The same information can also be reported more compactly by reference (see LINC code 48013.7) if the reference sequence has been catalogued by a registration authority such as RefSeq at NCBI. A reference sequence can be quite long.

Example answer: 241 GGAGTATCA GCACCTCAGG GGGACCTCTG CGAGTCTATA GCCTACTCTG TCAGAAAC C91 TATTCTCTAG T6ATGTCGA TGGACTCAGG TCTGATTCG TTTCTGATG GTCTGCTTCT 361 TTCACAGTAA CTA\*

Amino acid change type

Alllic State

\*Inclusive Copy Number Variation [CNV], Loss of Heterozygosity [LOH], Quantitative gene dosage

Result modifier

RNA/Protein consequences

Reports

Co-occurrence with deleterious mutations

Species conservation

Biochemical

This modifier can be used to correlate genetic findings with (e.g.) pharmacogenetic or biochemical results

Biophysical change

In-silico analyses

RNA Studies

Functional studies

Control data

Segregation data

Loss of normal allele in cancer

Genetic Test Interpretation

Limitations and Disclaimers (compulsory)

This section would describe the status of the result. Has it been validated? Is it research-use only? Are there known weaknesses? Is this study partial, in progress, complete, etc.

Result Interpretation (compulsory)

This section summarises the laboratory findings. What were the results of testing? What are the biological and genetic implications of this result?

Genetic Screen findings (optional)

Cancer status summary (optional)

\*Carrier identification interpretation of all identified DNA Markers and/or Individual Alleles along with any known clinical information for the benefit of aiding clinicians in understanding the results overall \*

Segregation summary (optional)

Clinical Interpretation (Compulsory)

This section summarises the clinical significance (if any) of the laboratory findings. It can take into account Family History or Clinical History.

Genotype clinical interpretation (optional)

Phenotype clinical interpretation (optional)

Conclusion (optional)

This is the final "tie it all together" field if not already done so above.

Interpretation modifier

As for Result modifier, see above.